retatrutide mechanism clinical trials 💉𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲'𝘀 𝗨𝗻𝗲𝘅𝗽𝗲𝗰𝘁𝗲𝗱 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁: 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂 𝗦𝗵𝗼𝘂𝗹𝗱 𝗞𝗻𝗼𝘄 𝗥𝗲𝘁𝗮𝘁𝗿𝘂𝘁𝗶𝗱𝗲: a new triple-agonist weight loss drug that is STILL IN TRIALS, is showing incredible results, with some Retatrutide: A Multi-Receptor Approach to

In the SURMOUNT-1 clinical trial, participants on the maximum dose achieved an average of 22.5% body weight loss over 72 weeksthe highest weight reduction ever observed in a phase 3 obesity trial

This was reported in the DURATION-1 (8.1% of the exenatide twice daily group, 17.2% of the exenatide once weekly group), LEAD-6 (6.4% with liraglutide versus 6.0% with exenatide twice daily), DURATION-5 (4.1% with exenatide twice daily, 7.0% with exenatide once weekly), DURATION-6 (3% in each group), and HARMONY-7 (10.4% with albiglutide compared with 11.0% with liraglutide)

BPC-157 possibly resulted in an upregulation of VEGF-a expression and acceleration of vascular tube formation

Great post, Alden

We ask for your permission before anything is loaded, as Google reCAPTCHA may use cookies and other technologies

Verified by HPLC + Mass Spectrometry